Verrica Pharmaceuticals (VRCA) Research & Development (2017 - 2026)
Verrica Pharmaceuticals (VRCA) posted quarterly Research & Development of $3.9 million for Q1 2026, up 69.0% year-over-year from $2.3 million in Q1 2025, and up 53.17% quarter-over-quarter from $2.5 million in Q4 2025.
Verrica Pharmaceuticals (VRCA) Research & Development (2017 - 2026) Analysis & Trends
Verrica Pharmaceuticals' Research & Development history runs 10 years deep, the most recent figure standing at $3.9 million for Q1 2026.
- In Q1 2026, Research & Development rose 69.0% year-over-year to $3.9 million; the TTM figure through Mar 2026 stood at $10.4 million (up 13.68% YoY), while the FY2025 annual figure was $8.9 million, down 25.21% from the prior year.
- Research & Development for Q1 2026 stood at $3.9 million, up from $2.5 million in the prior quarter.
- The five-year high for Research & Development was $6.5 million in Q3 2023, with the low at $1.2 million in Q4 2024.
- The 5-year median for Research & Development is $2.8 million (2022), against an average of $3.4 million.
- The sharpest annual moves came in 2023 and 2024: Research & Development surged 134.17% in 2023, then tumbled 78.05% in 2024.
- Verrica Pharmaceuticals' Research & Development stood at $3.0 million in 2022, then surged by 75.69% to $5.3 million in 2023, then sank by 78.05% to $1.2 million in 2024, then surged by 115.75% to $2.5 million in 2025, then soared by 53.17% to $3.9 million in 2026.
- Business Quant data shows VRCA's Research & Development at $3.9 million in Q1 2026, $2.5 million in Q4 2025, and $2.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Verrica Pharmaceuticals | 104.71 Mn | 93.51 Mn | - | 6.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.03 Mn |
| Mar 31, 2026 | 3.86 Mn |
| Dec 31, 2025 | 2.52 Mn |
| Sep 30, 2025 | 2.21 Mn |
| Jun 30, 2025 | 1.85 Mn |
| Mar 31, 2025 | 2.28 Mn |
| Dec 31, 2024 | 1.17 Mn |
| Sep 30, 2024 | 2.41 Mn |
| Jun 30, 2024 | 3.32 Mn |
| Mar 31, 2024 | 4.95 Mn |
| Dec 31, 2023 | 5.32 Mn |
| Sep 30, 2023 | 6.51 Mn |
| Jun 30, 2023 | 5.73 Mn |
| Mar 31, 2023 | 2.74 Mn |
| Dec 31, 2022 | 3.03 Mn |
| Sep 30, 2022 | 2.78 Mn |
| Jun 30, 2022 | 3.94 Mn |
| Mar 31, 2022 | 2.45 Mn |
| Dec 31, 2021 | -10.27 Mn |
| Sep 30, 2021 | 3.76 Mn |